JP2020183390A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020183390A5 JP2020183390A5 JP2020108654A JP2020108654A JP2020183390A5 JP 2020183390 A5 JP2020183390 A5 JP 2020183390A5 JP 2020108654 A JP2020108654 A JP 2020108654A JP 2020108654 A JP2020108654 A JP 2020108654A JP 2020183390 A5 JP2020183390 A5 JP 2020183390A5
- Authority
- JP
- Japan
- Prior art keywords
- gdf11
- antagonist
- pharmaceutical composition
- patient
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261718128P | 2012-10-24 | 2012-10-24 | |
| US61/718,128 | 2012-10-24 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018131952A Division JP2018184430A (ja) | 2012-10-24 | 2018-07-12 | 貧血の治療方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020183390A JP2020183390A (ja) | 2020-11-12 |
| JP2020183390A5 true JP2020183390A5 (cg-RX-API-DMAC10.html) | 2021-03-04 |
Family
ID=50545463
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015539751A Active JP6401172B2 (ja) | 2012-10-24 | 2013-10-23 | 貧血の治療方法 |
| JP2018131952A Pending JP2018184430A (ja) | 2012-10-24 | 2018-07-12 | 貧血の治療方法 |
| JP2020108654A Withdrawn JP2020183390A (ja) | 2012-10-24 | 2020-06-24 | 貧血の治療方法 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015539751A Active JP6401172B2 (ja) | 2012-10-24 | 2013-10-23 | 貧血の治療方法 |
| JP2018131952A Pending JP2018184430A (ja) | 2012-10-24 | 2018-07-12 | 貧血の治療方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20150266950A1 (cg-RX-API-DMAC10.html) |
| EP (2) | EP3527219A1 (cg-RX-API-DMAC10.html) |
| JP (3) | JP6401172B2 (cg-RX-API-DMAC10.html) |
| CN (3) | CN104981250A (cg-RX-API-DMAC10.html) |
| AU (4) | AU2013334660B2 (cg-RX-API-DMAC10.html) |
| CA (1) | CA2889286A1 (cg-RX-API-DMAC10.html) |
| HK (1) | HK1214504A1 (cg-RX-API-DMAC10.html) |
| NZ (1) | NZ747350A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2014066487A2 (cg-RX-API-DMAC10.html) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8128933B2 (en) | 2005-11-23 | 2012-03-06 | Acceleron Pharma, Inc. | Method of promoting bone growth by an anti-activin B antibody |
| BRPI0618947B1 (pt) | 2005-11-23 | 2022-07-19 | Acceleron Pharma Inc | Polipeptídeo actriia que se liga à ativina, polinucleotídeo isolado, polinucleotídeo recombinante, métodopara preparar um polipeptídeo actriia que se liga à ativina, preparação farmacêutica e uso de uma proteína de fusão actriia-fc para promover o crescimento ósseo e inibir a ressorção óssea |
| US8895016B2 (en) | 2006-12-18 | 2014-11-25 | Acceleron Pharma, Inc. | Antagonists of activin-actriia and uses for increasing red blood cell levels |
| TWI584815B (zh) | 2007-02-01 | 2017-06-01 | 艾瑟勒朗法瑪公司 | 活化素-ＡｃｔＲＩＩａ拮抗劑及其治療或預防乳癌之用途 |
| TW201627320A (zh) | 2007-02-02 | 2016-08-01 | 艾瑟勒朗法瑪公司 | 衍生自ＡｃｔＲＩＩＢ的變體與其用途 |
| MX2009008510A (es) | 2007-02-09 | 2010-01-15 | Acceleron Pharma Inc | Antagonistas de activina-actriia y usos para promover el crecimiento de huesos en pacientes con cancer. |
| CA2699936A1 (en) | 2007-09-18 | 2009-03-26 | Acceleron Pharma Inc. | Activin-actriia antagonists and uses for decreasing or inhibiting fsh secretion |
| DK3750552T5 (da) | 2008-08-14 | 2024-08-26 | Acceleron Pharma Inc | Gdf-fælder |
| US8216997B2 (en) | 2008-08-14 | 2012-07-10 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators |
| MX355042B (es) | 2009-06-08 | 2018-04-02 | Acceleon Pharma Inc | Metodos para aumentar adipositos termogenicos. |
| CN107267520A (zh) | 2009-06-12 | 2017-10-20 | 阿塞勒隆制药公司 | 截短的actriib‑fc融合蛋白 |
| ES2658292T3 (es) | 2009-11-17 | 2018-03-09 | Acceleron Pharma, Inc. | Proteínas ActRIIB y variantes y usos de las mismas con respecto a la inducción de la utrofina para el tratamiento de la distrofia muscular |
| CA2817008A1 (en) | 2010-11-08 | 2012-05-18 | Acceleron Pharma Inc. | Actriia binding agents and uses thereof |
| JP6401172B2 (ja) * | 2012-10-24 | 2018-10-10 | セルジーン コーポレイション | 貧血の治療方法 |
| RU2678117C2 (ru) | 2012-11-02 | 2019-01-23 | Селджин Корпорейшн | Антагонисты активина-actrii и их применение для лечения нарушений костной ткани и других нарушений |
| JP2017509647A (ja) * | 2014-03-21 | 2017-04-06 | アクセルロン ファーマ， インコーポレイテッド | アクチビンｂおよび／またはｇｄｆ１１の阻害によって赤血球レベルを増大させ、無効赤血球生成を処置する方法 |
| CN114699529A (zh) | 2014-06-13 | 2022-07-05 | 阿塞勒隆制药公司 | 用于治疗溃疡的方法和组合物 |
| MA41052A (fr) | 2014-10-09 | 2017-08-15 | Celgene Corp | Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii |
| MA41119A (fr) | 2014-12-03 | 2017-10-10 | Acceleron Pharma Inc | Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique |
| EP3227675B1 (en) | 2014-12-03 | 2023-03-15 | Celgene Corporation | Activin-actrii antagonists and uses for treating myelodysplastic syndrome |
| WO2016128523A1 (en) * | 2015-02-12 | 2016-08-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for predicting the responsiveness of a patient affected with malignant hematological disease to chemotherapy treatment and methods of treatment of such disease |
| TWI814187B (zh) * | 2015-05-13 | 2023-09-01 | 美商西建公司 | 使用ACTRII配位體捕捉以治療β-地中海型貧血 |
| EP3298034A4 (en) | 2015-05-20 | 2019-02-13 | Celgene Corporation | IN VITRO CELL CULTURE PROCEDURE FOR BETA THALASSEMIA BY MEANS OF ACTIVIN TYPE II RECEPTOR LIGANDS |
| EP3370754B1 (en) | 2015-11-04 | 2026-04-29 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating ineffective erythropoiesis |
| AU2017296040C1 (en) | 2016-07-15 | 2023-06-22 | Acceleron Pharma Inc. | Compositions and methods for treating pulmonary hypertension |
| LT3490582T (lt) | 2016-07-27 | 2024-07-25 | Acceleron Pharma Inc. | Kompozicijos, skirtos naudoti gydant mielofibrozę |
| CA3043184A1 (en) | 2016-11-10 | 2018-05-17 | Keros Therapeutics, Inc. | Activin receptor type iia variants and methods of use thereof |
| CN107011430B (zh) * | 2017-04-07 | 2020-09-01 | 哈尔滨医科大学 | 一种具有生物学活性的截短的生长分化因子11及其制备方法 |
| EP3706777B1 (en) | 2017-11-09 | 2024-05-22 | Keros Therapeutics, Inc. | Activin receptor type iia variants and methods of use thereof |
| IL320014A (en) | 2018-01-12 | 2025-06-01 | Keros Therapeutics Inc | Activin receptor type iib variants and methods of use thereof |
| IL278546B2 (en) * | 2018-05-09 | 2026-03-01 | Keros Therapeutics Inc | Activin receptor type IIA variants and methods of using them |
| WO2020257587A1 (en) * | 2019-06-19 | 2020-12-24 | Cornell University | Methods of promoting erythropoiesis and overcoming erythropoitein resistance in patients |
| EP4121088A4 (en) | 2020-03-20 | 2024-07-03 | Keros Therapeutics, Inc. | Methods of using activin receptor type iib variants |
| EP4121078A4 (en) | 2020-03-20 | 2024-08-14 | Keros Therapeutics, Inc. | ACTIVIN RECEPTOR TYPE II CHIMERAS AND METHODS OF USE THEREOF |
| US20230174620A1 (en) | 2020-04-28 | 2023-06-08 | Acceleron Pharma Inc. | Actrii proteins and use in treating post-capillary pulmonary hypertension |
| US12186370B1 (en) | 2020-11-05 | 2025-01-07 | Celgene Corporation | ACTRIIB ligand trap compositions and uses thereof |
| CN113801880B (zh) * | 2021-07-27 | 2024-11-01 | 浙江大学 | 一种通过靶向敲除基因建立的早衰细胞模型及其sgRNA、构建方法和应用 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5096815A (en) | 1989-01-06 | 1992-03-17 | Protein Engineering Corporation | Generation and selection of novel dna-binding proteins and polypeptides |
| US5198346A (en) | 1989-01-06 | 1993-03-30 | Protein Engineering Corp. | Generation and selection of novel DNA-binding proteins and polypeptides |
| DE69534468T2 (de) * | 1994-07-08 | 2006-07-13 | The Johns Hopkins University School Of Medicine | Wachstums-differenzierungsfaktor-11 |
| US7795202B2 (en) | 1997-08-04 | 2010-09-14 | Neurorepair, Inc. | Methods for treating a neurological disorder by peripheral administration of a transforming growth factor alpha (TGF-a) |
| NZ509609A (en) * | 1998-07-28 | 2003-11-28 | Univ Johns Hopkins Med | Disrupting growth differentiation factor-11 (GDF-11) to increase the muscle and bone tissue in animals |
| TWI329129B (en) | 2001-02-08 | 2010-08-21 | Wyeth Corp | Modified and stabilized gdf propeptides and uses thereof |
| US7320789B2 (en) | 2001-09-26 | 2008-01-22 | Wyeth | Antibody inhibitors of GDF-8 and uses thereof |
| PL374966A1 (en) | 2002-02-21 | 2005-11-14 | Wyeth | Follistatin domain containing proteins |
| US7261893B2 (en) | 2002-10-22 | 2007-08-28 | Wyeth | Neutralizing antibodies against GDF-8 and uses therefor |
| JP2008507288A (ja) | 2004-07-23 | 2008-03-13 | アクセルロン ファーマ インコーポレーテッド | ＡｃｔＲＩＩ受容体ポリペプチド、方法、および組成物 |
| JP2008534607A (ja) * | 2005-03-30 | 2008-08-28 | ワイス | Ｂｍｐを投与することによって毛髪の成長を刺激するための方法 |
| AU2006264339A1 (en) * | 2005-07-01 | 2007-01-11 | Acceleron Pharma Inc. | Lefty, Lefty derivatives and uses therof |
| UA92504C2 (en) | 2005-10-12 | 2010-11-10 | Эли Лилли Энд Компани | Anti-myostatin monoclonal antibody |
| US20100028332A1 (en) | 2006-12-18 | 2010-02-04 | Acceleron Pharma Inc. | Antagonists of actriib and uses for increasing red blood cell levels |
| CA2672758C (en) | 2006-12-18 | 2019-07-30 | Acceleron Pharma Inc. | Activin-actrii antagonists and uses for increasing red blood cell levels |
| US8895016B2 (en) | 2006-12-18 | 2014-11-25 | Acceleron Pharma, Inc. | Antagonists of activin-actriia and uses for increasing red blood cell levels |
| TW201627320A (zh) | 2007-02-02 | 2016-08-01 | 艾瑟勒朗法瑪公司 | 衍生自ＡｃｔＲＩＩＢ的變體與其用途 |
| TW201718635A (zh) | 2007-03-06 | 2017-06-01 | 安美基公司 | 變異之活動素受體多肽及其用途 |
| US8236751B2 (en) | 2007-03-07 | 2012-08-07 | The Johns Hopkins University | Methods of increasing muscle mass using follistatin-like related gene (FLRG) |
| CA2699936A1 (en) | 2007-09-18 | 2009-03-26 | Acceleron Pharma Inc. | Activin-actriia antagonists and uses for decreasing or inhibiting fsh secretion |
| KR20110031951A (ko) * | 2008-06-26 | 2011-03-29 | 악셀레론 파마 인코포레이티드 | 액티빈-ａｃｔｒｉｉａ의 길항물질 및 적혈구 수준을 증가시키기 위한 이들의 용도 |
| DK3750552T5 (da) | 2008-08-14 | 2024-08-26 | Acceleron Pharma Inc | Gdf-fælder |
| US8216997B2 (en) * | 2008-08-14 | 2012-07-10 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators |
| KR102170682B1 (ko) * | 2009-08-13 | 2020-10-28 | 악셀레론 파마 인코포레이티드 | 적혈구 수준을 증가시키기 위한 ｇｄｆ 트랩과 에리트로포이에틴 수용체 활성인자의 병용 |
| JO3340B1 (ar) | 2010-05-26 | 2019-03-13 | Regeneron Pharma | مضادات حيوية لـعامل تمايز النمو 8 البشري |
| WO2012027065A2 (en) * | 2010-08-27 | 2012-03-01 | Celgene Corporation | Combination therapy for treatment of disease |
| CA2817008A1 (en) * | 2010-11-08 | 2012-05-18 | Acceleron Pharma Inc. | Actriia binding agents and uses thereof |
| JP6401172B2 (ja) * | 2012-10-24 | 2018-10-10 | セルジーン コーポレイション | 貧血の治療方法 |
-
2013
- 2013-10-23 JP JP2015539751A patent/JP6401172B2/ja active Active
- 2013-10-23 US US14/438,127 patent/US20150266950A1/en not_active Abandoned
- 2013-10-23 CN CN201380067832.9A patent/CN104981250A/zh active Pending
- 2013-10-23 CN CN202011541918.9A patent/CN112933223A/zh active Pending
- 2013-10-23 EP EP19151143.5A patent/EP3527219A1/en not_active Withdrawn
- 2013-10-23 AU AU2013334660A patent/AU2013334660B2/en active Active
- 2013-10-23 CN CN202011542063.1A patent/CN112957462A/zh active Pending
- 2013-10-23 EP EP13849960.3A patent/EP2911682A4/en not_active Withdrawn
- 2013-10-23 NZ NZ747350A patent/NZ747350A/en unknown
- 2013-10-23 CA CA2889286A patent/CA2889286A1/en not_active Abandoned
- 2013-10-23 HK HK16102359.3A patent/HK1214504A1/zh unknown
- 2013-10-23 WO PCT/US2013/066353 patent/WO2014066487A2/en not_active Ceased
-
2018
- 2018-07-12 JP JP2018131952A patent/JP2018184430A/ja active Pending
- 2018-11-02 AU AU2018256635A patent/AU2018256635A1/en not_active Abandoned
-
2020
- 2020-05-15 AU AU2020203198A patent/AU2020203198B2/en active Active
- 2020-06-24 JP JP2020108654A patent/JP2020183390A/ja not_active Withdrawn
-
2022
- 2022-03-21 AU AU2022201923A patent/AU2022201923A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016503398A5 (cg-RX-API-DMAC10.html) | ||
| Sandhu et al. | A case control study to evaluate the impact of colchicine on patients admitted to the hospital with moderate to severe COVID‐19 infection | |
| Zhu et al. | Energy metabolism in cancer stem cells | |
| Greenblatt et al. | Interaction of warfarin with drugs, natural substances, and foods | |
| Zhu et al. | Resveratrol alleviates dextran sulfate sodium-induced acute ulcerative colitis in mice by mediating PI3K/Akt/VEGFA pathway | |
| Qi et al. | MET inhibitors for treatment of advanced hepatocellular carcinoma: A review | |
| Naguib et al. | Prevention of paclitaxel-induced neuropathy through activation of the central cannabinoid type 2 receptor system | |
| Lövborg et al. | Inhibition of proteasome activity, nuclear factor‐KB translocation and cell survival by the antialcoholism drug disulfiram | |
| Burnett et al. | Oral interleukin 11 as a countermeasure to lethal total-body irradiation in a murine model | |
| Wallerstedt et al. | Risk of clinically relevant bleeding in warfarin‐treated patients—influence of SSRI treatment | |
| Ahmed et al. | Oral administration of tualang and Manuka honeys modulates breast cancer progression in Sprague‐Dawley rats model | |
| RU2014110184A (ru) | Комбинации терапевтических средств, предназначенные для лечения рака | |
| Feng et al. | Cyproheptadine, an antihistaminic drug, inhibits proliferation of hepatocellular carcinoma cells by blocking cell cycle progression through the activation of P38 MAP kinase | |
| Yao et al. | Synergistic cytotoxic effects of arsenite and tetrandrine in human breast cancer cell line MCF-7 | |
| Wang et al. | Dexamethasone ameliorates H2S-induced acute lung injury by alleviating matrix metalloproteinase-2 and-9 expression | |
| Yu et al. | Tetramethylpyrazine-mediated suppression of C6 gliomas involves inhibition of chemokine receptor CXCR4 expression | |
| Park et al. | Comparative efficacy of sunitinib versus sorafenib as first-line treatment for patients with metastatic renal cell carcinoma | |
| BR112022004587A2 (pt) | Métodos para tratar narcolepsia tipo 1, diminuir eventos tipo cataplexia, aumentar concentração de cálcio intracelular, aumentar latência de sono em manutenção de teste de insônia, melhorar classificação de escaça de sonolência de karolinska, tratar uma doença associada a nível de orexina reduzido, aumentar alerta, melhorar classificação de escala de sonolência epworth, e, composição farmacêutica | |
| Aoki et al. | Histone H3 lysine-trimethylation markers are decreased by recombinant methioninase and increased by methotrexate at concentrations which inhibit methionine-addicted osteosarcoma cell proliferation | |
| Awasthi et al. | Enhancing sorafenib-mediated sensitization to gemcitabine in experimental pancreatic cancer through EMAP II | |
| D’Alessandro et al. | Antagonism of sorafenib and regorafenib actions by platelet factors in hepatocellular carcinoma cell lines | |
| Ebrahimpour et al. | Esomeprazole attenuates inflammatory and fibrotic response in lung cells through the MAPK/Nrf2/HO1 pathway | |
| Bauersachs | Managing venous thromboembolism with novel oral anticoagulants in the elderly and other high-risk patient groups | |
| Guo et al. | The glutaminase inhibitor compound 968 exhibits potent in vitro and in vivo anti-tumor effects in endometrial cancer | |
| Nishio et al. | Effect of exogenous retinoic acid on tooth movement and periodontium healing following tooth extraction in a rat model |